Summary
Two cases of acute myocardial ischaemia precipitated by oral ergotamine therapy for migraine are described from patients with no previous history of ischaemic heart disease. The relevant literature is briefly reviewed.
Case 1
An otherwise healthy 50-year-old man had suffered from migrainous neuralgia for 8 years. In recent months he had been taking up to 40 mg of ergotamine every week (as sublingual Lingraine)
Correspondence: Dr N. Snell, 16 Albert Road, Henley, Oxon. to control his attacks, and had occasionally noticed severe pain in his forearms some hours after taking the tablets. Early on the morning of admission he took his usual dose of 10 mg ergotamine to abort an impending attack, with success. At midday he developed forearm pain accompanied by severe central chest pain, and was brought to hospital. Physical examination was unremarkable, but an electrocardiogram ( Fig. 1) showed gross elevation of the S-T segment in the anteroseptal leads, and he was admitted with a suspected myocardial infarct. Ninety min later his ECG had returned to almost normal, and he remained pain-free thereafter; however, on the fourth day after admission repolarization changes developed in the septal leads of his ECG. Serial estimations of serum creatine kinase, aspartate transaminase, and hydroxybutyrate dehydrogenase, on days 1, 2, 5, and 7 after admission, were within normal limits. His further course was uneventful; he was advised to avoid medications containing ergotamine in the future. When reviewed as an out-patient at 4 months and 9 months after discharge he had remained symptom-free despite returning to vigorous work, and his ECG had returned to normal.
Case 2
A 40-year-old woman had suffered from classical migraine for 4 years; this was controlled by ergotamine (as Migril tablets) her total dose never exceeding 2 mg in 1 week. On the afternoon of admission she felt a headache developing so took one tablet (containing 2 mg ergotamine) and fell asleep for approximately 10 min, being awakened by severe central chest pain radiating to the left arm. Her general practitioner was called and gave sublingual glyceryl trinitrate with some relief, followed by intravenous morphine. She was admitted to hospital. On arrival, physical examination was normal; her initial ECG was unremarkable (Fig. 2) in the anteroseptal leads, which persisted over the next 10 days. Cardiac enzyme estimations on days 1 and 4 were normal. She was advised to avoid ergotamine in future. At review 6 months after discharge her ECG had returned to normal, and she had suffered no further chest pain.
Discussion
Both these patients developed unequivocal angina following the use of ergotamine. The ECG changes in the first case correspond to those described in the Prinzmetal variety of angina, in which pain due to coronary artery spasm develops at rest, the ECG characteristically showing transient S-T segment elevation. Prinzmetal angina often occurs in subjects with anatomically normal coronary arteries, and attacks can be provoked by various pharmacological agents including methacholine (Endo et al., 1976) and ergometrine (Higgins et al., 1976) ; it has not previously been described after ergotamine administration. Leon-Sotomayor (1974) has described twelve patients with a syndrome characterized by migraine headaches, coronary artery spasm, and functional hypoglycaemia; it was noted that ergometrine improved the headache but worsened the chest pain. It may be that the first patient was predisposed to Prinzmetal angina and this was precipitated by his recently increased ergotamine intake.
Ergotamine has been used in the treatment of migraine since 1883; considering the number of patients regularly taking this potent vasoconstrictive drug, it is perhaps surprising that severe side effects are not reported more often; those described in the literature include ischaemia of the extremities (Felix and Carroll, 1970; Imrie, 1973) , papillitis due to vasoconstriction around the optic nerve (Gupta and Strobos, 1972) and renal arterial spasm (Fedotin and Hartman, 1970) . There have been several reports of myocardial ischaemia due to the use of ergotamine, for indications other than migraine, in patients with known heart disease (Labbe et al., 1929a; Lichtman, 1936; Scherf and Schlachman, 1948; McNerney and Leedham, 1950) , and also in a case of thyrotoxicosis (Labbe, Justin-Besanion and Gouyen, 1929b) . In a survey of the literature four cases of myocardial ischaemia occurring in previously healthy migraine sufferers have been found; in two of these angina occurred (Bailey Carter, 1940; Bemreiter, 1965) , one developed a probable myocardial infarct (Fuchs and Blumenthal, 1950) , and one a definite infarct (Goldfischer, 1960) . A further complication of the use of ergotamine for migraine is that the drug itself may cause headache, and this may lead to an increase in dose by the patient, and the establishment of a vicious circle (Wainscott, Volans and Wilkinson, 1974) . It should be emphasized that the recoinmended dosage (a maximum of 4 mg ergotamine in 1 day, and 10 mg in any 1 week) should never be exceeded even in healthy patients; it should be used with caution in cases of liver disease since it is metabolized in the liver; and its, use is absolutely contraindicated in known cases of ischaemic heart disease or peripheral vascular insufficiency.
